Invitae (NYSE:NVTA) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA) in a research report released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Invitae Stock Up 900.0 %

NVTA stock opened at $0.01 on Wednesday. Invitae has a one year low of $0.02 and a one year high of $0.02. The firm has a market capitalization of $2.40 million, a PE ratio of 0.00 and a beta of 1.59.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC increased its holdings in shares of Invitae by 404.6% in the 3rd quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 50,600 shares in the last quarter. Financial Gravity Asset Management Inc. lifted its position in shares of Invitae by 1,799.5% during the 3rd quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 70,037 shares during the period. SG Americas Securities LLC boosted its stake in shares of Invitae by 90.7% during the 4th quarter. SG Americas Securities LLC now owns 91,937 shares of the medical research company’s stock worth $58,000 after acquiring an additional 43,717 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new stake in shares of Invitae during the 4th quarter worth approximately $144,000. Finally, Green Alpha Advisors LLC grew its holdings in shares of Invitae by 138.4% in the 4th quarter. Green Alpha Advisors LLC now owns 452,585 shares of the medical research company’s stock worth $284,000 after acquiring an additional 262,760 shares during the period. Hedge funds and other institutional investors own 61.28% of the company’s stock.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.